Igm Biosciences CBO Decker sells $5611 in stock

Published 26/07/2025, 22:00
Igm Biosciences CBO Decker sells $5611 in stock

Lisa Lynn Decker, Chief Business Officer of IGM Biosciences (NASDAQ:IGMS), sold 4,409 shares of common stock on July 23, 2025, for a total of $5611. The transaction comes as IGM Biosciences, currently valued at $76.4 million, has seen its stock decline nearly 89% over the past year. According to InvestingPro analysis, the company appears undervalued at current levels.

The shares were sold at a weighted average price of $1.2728, with individual sales prices ranging from $1.27 to $1.275. The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Decker directly owns 68,169 shares of IGM Biosciences. InvestingPro data reveals the company holds more cash than debt on its balance sheet, though it’s quickly burning through available funds. Discover 8 more exclusive ProTips and comprehensive insider trading analysis with an InvestingPro subscription.

In other recent news, IGM Biosciences has announced a definitive merger agreement with Concentra Biosciences. Under the terms of the deal, Concentra will acquire IGM Biosciences for $1.247 in cash per share, along with a non-tradeable contingent value right (CVR). This CVR entitles shareholders to 100% of IGM’s closing net cash exceeding $82 million and 80% of any net proceeds from the sale of certain product candidates and intellectual property within a year of the transaction’s closing. In another development, IGM Biosciences has ended its collaboration and license agreement with Genzyme Corporation, a Sanofi (NASDAQ:SNY) entity. This agreement, originally established in March 2022, was focused on developing IgM antibodies for diseases like cancer and immunological disorders. The termination notice was received by IGM Biosciences on May 5, 2025, and will be effective 30 days from that date. Both IGM Biosciences and Genzyme Corporation have agreed that continuing their collaboration is not in their best interests.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.